The Malaysian Burden of Disease Study: Protocol for Mortality, Morbidity, and Risk Factor Evaluation
JMIR Research Protocols · 2025
DOI: 10.2196/71583 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift JMIR Research Protocols, 2025. Verfasst von Wan-Fei Khaw und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Public Health, National Institutes of Health, Ministry of Health Malaysia, Shah Alam, Selangor, Malaysia. Hauptthemen laut MEDLINE: Cost of Illness. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Knowledge of the burden of disease at the national level is crucial for understanding regional health patterns and epidemiological trends. Regular updates and methodological enhancements are essential to produce accurate estimates that effectively represent the current health landscape, thereby assisting policymakers in resource allocation and strategic planning.
Objective
The objective of this study protocol is to revise the list of diseases and injuries; estimate years of life lost (YLLs), years lived with disability (YLDs), and disability-adjusted life years (DALYs) in phase 1; and identify the list of risk factors and determine risk-attributable burdens in phase 2.
Methods
The Malaysian Burden of Disease (MBOD) Study adopts the Global Burden of Disease Study approach, using various metrics to quantify health loss related to specific diseases, injuries, and risk factors. These metrics include deaths, YLLs, YLDs, and DALYs, which are calculated in terms of counts, age-specific rates, and all-age rates. In addition, this MBOD Study calculates risk-attributable deaths, YLLs, YLDs, and DALYs for all relevant risk factors. This study also conducts focus group discussions to develop the lists of diseases and injuries as well as risk factors.
Results
By December 2024, we had successfully completed the focus group discussions, which led to the development of an updated and comprehensive list of diseases and injuries. Furthermore, mortality data collection is complete, and the calculation of YLLs is currently in progress. The YLD calculation is expected to conclude by the end of 2025. While phase 1 is underway, phase 2, which addresses risk factor estimation, is scheduled for completion in mid-2026.
Conclusions
This MBOD Study offers a comprehensive and current framework for assessing the burden of disease in Malaysia, with continuous improvement initiatives to enhance the list of diseases and injuries and refine the methodology for more accurate estimation and risk factor analysis. International Registered Report Identifier (IRRID) DERR1-10.2196/71583
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute for Public Health, National Institutes of Health, Ministry of Health Malaysia, Shah Alam, Selangor, Malaysia.
- Institute for Medical Research, National Institutes of Health, Ministry of Health Malaysia, Shah Alam, Selangor, Malaysia.
ORCID-Profile: Wan-Fei Khaw, Nazirah Alias, Sin Wan Tham, Kim Sui Wan, Nur Hamizah Nasaruddin, Nur Diyana Rosnan, Shubash Shander Ganapathy, Mohd Azahadi Omar
Zitieren
APA
Khaw, W. F., Alias, N., Tham, S. W., Wan, K. S., Nasaruddin, N. H., Rosnan, N. D., Ganapathy, S. S., & Omar, M. A. (2025). The Malaysian Burden of Disease Study: Protocol for Mortality, Morbidity, and Risk Factor Evaluation. JMIR Research Protocols. https://doi.org/10.2196/71583
Vancouver
Khaw WF, Alias N, Tham SW, Wan KS, Nasaruddin NH, Rosnan ND, et al. The Malaysian Burden of Disease Study: Protocol for Mortality, Morbidity, and Risk Factor Evaluation. JMIR Research Protocols. 2025. doi:10.2196/71583
BibTeX
@article{Khaw2025,
author = {Khaw, Wan-Fei and Alias, Nazirah and Tham, Sin Wan and Wan, Kim Sui and Nasaruddin, Nur Hamizah and Rosnan, Nur Diyana and Ganapathy, Shubash Shander and Omar, Mohd Azahadi},
title = {The Malaysian Burden of Disease Study: Protocol for Mortality, Morbidity, and Risk Factor Evaluation},
journal = {JMIR Research Protocols},
year = {2025},
doi = {10.2196/71583}
}
EUVIMED